Skip to main content
Top

Reproducibility of 18F-Sodium Fluoride Positron Emission Tomography for Assessing Microcalcification in Coronary Arterial and Thoracic Aortic Atherosclerosis: Is the Signal below the Resolution of PET?

Published in:

Abstract

Purpose of Review

The rising prevalence of atherosclerosis has prompted the development of novel diagnostic methods capable of identifying early-stage disease when therapeutic interventions may be most effective. 18F-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT) is a molecular imaging technique that can quantify subclinical microcalcification in arterial plaque. The focus of this review article is to discuss the utility of 18F-NaF PET/CT in assessing atherosclerotic disease of major susceptible blood vessels, particularly the coronary arteries and thoracic aorta.

Recent Findings

18F-NaF uptake observed on PET imaging demonstrates promising potential as a marker of atherosclerotic burden in individual coronary arteries, whole heart segmentations, and the thoracic aorta. Global versus focal assessment of 18F-NaF uptake in small arteries is a significant source of methodological heterogeneity among studies.

Summary

The accuracy and reproducibility of 18F-NaF PET/CT may be improved by standardized quantification methods in light of the limited spatial resolution of PET, particularly through the use of techniques to evaluate global atherosclerotic burden.
Title
Reproducibility of 18F-Sodium Fluoride Positron Emission Tomography for Assessing Microcalcification in Coronary Arterial and Thoracic Aortic Atherosclerosis: Is the Signal below the Resolution of PET?
Authors
Ondrej Fanta
Shiv Patil
Thomas Werner
Drew A. Torigian
Abass Alavi
Publication date
01-12-2025
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 1/2025
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-025-02240-9
This content is only visible if you are logged in and have the appropriate permissions.

Next-generation MRI contrast agents: preparing the field (Link opens in a new window)

New MRI contrast agents are reshaping diagnostic imaging, promising lower gadolinium exposure amid evolving practice guidelines. How can you optimise contrast selection, dosing, and patient care in this rapidly advancing field?

This content is intended for healthcare professionals outside of the UK.

Independent Medical Education Grant:
  • Bayer HealthCare Pharmaceuticals Inc.
Learn more Link opens in a new window
Image Credits
Abstract graphic of layered, concentric circular shapes in bright green, pink, blue, and purple on a dark blue background. The rings and segments form a complex radial pattern without text/© Springer Health+ IME